Copyright
©The Author(s) 2021.
World J Clin Cases. Jul 26, 2021; 9(21): 6041-6048
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.6041
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.6041
Time of therapy | Treatment | Best efficacy | PFS (mo) |
November 2014 | ABVD × 6 cycles | CR | 16 |
March 2016 | AVD × 1 cycle | Unknown | - |
September 2016 | AVD × 1 cycle | Unknown | - |
October 2016 | GVD × 4 cycles | PD | 4.8 |
October 2017 | GVD × 6 cycles | SD | 8.8 |
July 2018 | ESHAP × 1 cycle | PD | 0.9 |
October 2018 | AK105 × 9 cycles | PR | 3.5 |
July 2019 | IBI188 × 16 wk | SD | 3.6 |
November 2019 | DICE × 2 cycles | PD | 1.3 |
February 2020 | F0002-ADC × 1 cycle | PD | 0.6 |
March 2020 | Decitabine plus tislelizumab | PR | 11.5 |
Result | Normal range | |
Hematology | ||
White blood cell count | 20.81 × 109/L | 4.0-10.0 |
Red blood cell count | 3.17 × 1012/L | 3.5-5.5 |
Hemoglobin | 87 g/L | 120.0-160.0 |
Hematocrit | 28.8% | 37.0-49.0 |
MCV | 91 fl | 82.0-92.0 |
MCH | 27.3 pg | 27.0-31.0 |
MCHC | 300 g/L | 320.0-360.0 |
Platelets | 384 × 109/L | 100.0-350.0 |
Lymphocytes | 0.96 × 109/L | 1.0-5.0 |
Monocytes | 0.24 × 109/L | 0.2-0.8 |
Neutrophils | 19.59 × 109/L | 2.0-8.0 |
Eosinophils | 0 × 109/L | 0.1-0.5 |
Basophils | 0.02 × 109/L | 0.0-0.1 |
ESR | ||
Coagulation | ||
APTT | 59.3 s | 24.0-39.0 |
Thrombin time | 16.6 s | 14.0-21.0 |
Prothrombin time | 12.6 s | 11.0-14.0 |
INR | 1.11 | 0.8-1.5 |
Prothrombin activity | 81.9% | 70.0-130.0 |
Fibrinogen | 942.1 mg/dL | 200.0-400.0 |
Biochemistry | ||
C-reactive protein | 106.3 mg/L | < 8.0 |
Procalcitonin | 0.47 ng/mL | < 0.5 |
Glucose | 7.24 mmol/L | 3.6-6.1 |
Creatinine | 57 µmol/L | 50.0-130.0 |
MDRD GFR | > 60 mL/min | > 60 |
Uric acid | 318 µmol/L | 90.0-420.0 |
Lactate dehydrogenase | 260 IU/L | 110.0-240.0 |
ALB | 40.1 g/L | 35.0-55.0 |
TP | 69.4 g/L | 60.0-80.0 |
Alkaline phosphatase | 178 IU/L | 40.0-160.0 |
Serum iron | 9.9 µmol/L | 10.6-28.3 |
Serum ferritin | 7585 µg/L | 30.0-400.0 |
UIBC | 20 µmol/L | 19.7-66.2 |
TIBC | 29.9 µmol/L | 40.8-76.6 |
Total cholesterol | 4.66 mmol/L | 2.84-5.68 |
Triglycerides | 0.97 mmol/L | 0.56-1.7 |
Hormones | ||
TSH | 3.47 mIU/L | 0.27-4.2 |
FT3 | 3.59 pmol/L | 3.1-6.8 |
FT4 | 17.34 pmol/L | 12.0-22.0 |
Electrolytes | ||
Sodium | 137 mmol/L | 135.0-145.0 |
Potassium | 4.47 mmol/L | 3.5-5.3 |
Calcium-total | 2.35 mmol/L | 2.12-2.75 |
Phosphates inorganic | 0.83 mmol/L | 0.69-1.6 |
Liver enzymes | ||
ALT | 25 IU/L | 0.0-40.0 |
AST | 23 IU/L | 0.0-45.0 |
GGT | 151 IU/L | 10.0-50.0 |
DBIL | 3.0 µmol/L | 0.0-6.0 |
Total bilirubin | 9.4 µmol/L | 1.7-20.0 |
Virology tests | ||
Anti-HCV | Negative | |
HbsAg | Negative | |
Anti-HIV | Negative |
- Citation: Ding XS, Mi L, Song YQ, Liu WP, Yu H, Lin NJ, Zhu J. Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report. World J Clin Cases 2021; 9(21): 6041-6048
- URL: https://www.wjgnet.com/2307-8960/full/v9/i21/6041.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i21.6041